Audited Financial Results for the quarter and year ended on 31st March, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.2 pts less than Nifty Microcap 250 and 5.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board approved audited standalone financial results for FY25 with an unmodified (clean) audit opinion from the statutory auditor. Profit before tax rose to Rs. 115.51 lakhs from Rs. 98.73 lakhs in FY24, an increase of about 17%. Total assets grew sharply to Rs. 1,629.58 lakhs from Rs. 1,080.87 lakhs, driven largely by a jump in inventories (Rs. 446.49 lakhs vs Rs. 106.42 lakhs) and trade receivables (Rs. 189.82 lakhs vs Rs. 69.90 lakhs). However, the company reported negative cash flow from operations of Rs. 363.71 lakhs, compared with a positive Rs. 212.08 lakhs last year. The board also approved the audited results, the directors' report, notice of the 32nd AGM, and the appointment of M/s Meenu Maheshwari & Associates as Secretarial Auditor for five years.
While headline profitability improved, the sharp swing to negative operating cash flow and the buildup of inventory and receivables funded by new borrowings of Rs. 381.35 lakhs is a watch item for shareholders, as it points to working-capital stress that may pressure liquidity in the near term.